Patrick Campbell

Using data and eligibility criteria from the STEP 1 trial, a California-based team estimates 93 million US adults met criteria for semaglutide 2.4 mg and use could prevent 1.5 million incident cardiovascular events over a 10-year period.

An analysis of data from a NYC-based health system indicate more than 1 in 5 people hospitalized for COVID-19 and 1 in 10 nonhospitalized COVID-19 patients went on to develop persistent hypertension 6 months later.

With approval, aflibercept 8 mg becomes the first and only treatment approved in wet AMD and DME for immediate dosing at 8-week and up to 16-week intervals following 3 initial monthly doses.

The FDA approval of pozelimab (Veopoz) makes it the first and only treatment indicated for children and adults with CHAPLE disease.

A study led by Massachusetts General Hospital is offering insight into the antibody response achieved with each dose of mRNA vaccines among heart and lung transplant recipients relative to their healthy counterparts.

A posthoc analysis of the pivotal SOLOIST-WHF trial provides insight into the effects of sotagliflozin use on risk of cardiovascular mortality and heart failure readmissions at 90 days.

In a Q&A, Clipper Young, PharmD, MPH, discusses the Pharm2Home Initiative based on his presentation from ADCES 2023 and describes the impact of community-driven, pharmacist-led interventions to improve health literacy in those with chronic disease.

Michael J. Blaha, MD, MPH, discusses his interpretation of the growing data detailing the role of inflammation as a driver of cardiovascular risk and how clinicians can identify patients who stand to benefit most from colchicine 0.5 mg tablets.

Joshua Neumiller, PharmD, takes part in a Q&A on the role of deprescribing in older adults with diabetes mellitus based on a presentation from the Association of Diabetes Care and Education Specialists 2023 annual meeting.

In a recent Q&A, Michael Blaha, MD, discusses how he views the ideal role of cardiologists in the management of obesity and how this role could change based on the results of the SELECT trial.

At ADCES 2023, Halis Akturk, MD, presented data calling attention to the risk of hyperglycemic ketosis-cannabis hyperemesis syndrome in people with type 1 diabetes.

Novo Nordisk has announced topline data from the SELECT trial, which suggest use of once-weekly semaglutide 2.4 mg was associated with a statistically significant 20% reduction in 3-point MACE among a cohort with overweight or obesity and established cardiovascular disease.

An analysis of real-world data provides an overview of the effects of GLP-1 receptor agonist and SGLT2 inhibitor use among adults with type 1 diabetes.

The July 2023 cardiology month in review features a Class I recall from the FDA, the latest recommendation statement from the USPSTF, and an update on 3 agents in the pipeline.

An analysis of data from more than 80,000 patients using statins suggests the initial benefit on LDL-C reduction was greater for older patients than younger patients.

Our July 2023 endocrinology month in review features an FDA approval, topline results from a pair of major trials, and a pair of new guidelines related to the management and diagnosis of diabetes.

An analysis of 7 international, longitudinal studies with nearly 20,000 patients details apparent increases in risk associated with daily alcohol consumption among healthy adults.

Using NHANES data, along with deidentified data from the Optum database, investigators estimate the prevalence of albuminuria testing among people with hypertension or diabetes as well as how the presence or lack of testing might influence prescription of CKD therapies.

The FDA has announced Abiomed has initiated a recall of all left-sided Impella pumps, citing inadequate instructions for use as it pertains to precautions to take with patients who have undergone TAVR.

On July 27, 2023, Eli Lilly and Company announced topline results of the SURMOUNT-3 and SURMOUNT-4 trials, with both trials achieving all primary endpoints of interest and full results scheduled to be presented later this year.

An analysis of a nationwide sample of more than 30,000 clinicians provides insight into rates of HPV vaccination among US adolescents and how changes in reimbursement rate might encourage increased vaccination rates.

A secondary analysis of ASPREE is bringing the role of aspirin in primary prevention settings further into question, suggesting daily use of low-dose aspirin was associated with a 38% increase in intracranial bleeding in older adults.

A study from Denmark leveraging more than 40 million years of follow-up data from patients dating back to the 1950s offers insight into the apparent increase in the risk of myocardial infarction associated with pregnancy loss in women and whether this same effect is observed in male partners.

The American Diabetes Association, together with the American Association of Clinical Chemistry, has released a new, 49-page document outlining optimized guidance for use of laboratory analysis in the diagnosis and management of diabetes.

Data from a phase 1, first-in-human trial of NI006 suggests the agent could have a potential role in the management of transthyretin amyloid cardiomyopathy.

A multipart, phase 1 trial provides evidence demonstrating the safety of zilebesiran, an RNA interference agent, which appeared to have a favorable safety profile among adult patients with hypertension.

New data presented at the 12th International AIDS Society Conference on HIV Science suggests use of statin therapy in a primary prevention cohort of patients with HIV on antiretroviral therapy was associated with a 35% reduction in risk of cardiovascular events.

A single-center retrospective study is offering clinicians insight into the effects of biosimilar infliximab use on weight, height, and BMI trajectories in pediatric patients with inflammatory bowel disease.

A systematic review of 55 studies conducted in the US and abroad details the effects of private equity ownership in health care settings on costs to patients/payers as well as clinical outcomes.

An analysis of EHR data recorded from 2018-2022 within Duke University Medical Center-affiliated diabetes care centers suggests the increased rate of new-onset type 1 and type 2 diabetes observed during the first year of the pandemic persisted through 2022.